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doi:10.1016/j.ejvs.2008.12.024Abstract Preliminary events leading to the rupture of atherosclerotic plaques or aneurysmal
wall expansion undoubtedly are linked to altered and increased metabolism of cells in the
vascular wall. To allow in vivo identification of this local activity, imaging techniques such
as positron emission tomography (PET) and contrast ultrasonography may be used. However,
the use of complementary multimodal imaging methods, such as computed tomography
(CT), magnetic resonance imaging (MRI), single photon emission computed tomography
(SPECT), etc., can inform about other processes, including vascular wall calcification, haemo-
siderin deposits, apoptosis and accumulation of activated platelets in the arterial wall. Such
techniques may be used as an adjunct in following the evolution of the disease, as well as
having crucial roles as molecular and cellular probes of arterial disease. Therefore, functional
imaging techniques may be able to help us take more reliable decisions on the need for
medical or surgical treatment of arterial disease.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Conventional imaging of the vascular tree using ultrasound
(US), computed tomography (CT), magnetic resonance
imaging (MRI) and contrast angiography gives us anatomical
and morphological information about localised vascular
disease. However, recently available imaging techniques
can provide a molecular and cellular assessment of athe-
rothrombosis at the level of the arterial wall.6 71 63; fax:þ32 4 366 71 64.
be (N. Sakalihasan).
ty for Vascular Surgery. PublisheKnowledge of the biological activities associated with
the progression of atherosclerosis towards clinical expres-
sion in humans has evolved considerably in the last years. In
this article, atherosclerosis will include occlusive forms
(stenosis) and dilating forms (abdominal aortic aneurysm,
AAA). The common role of haemorrhage and thrombosis,
and the angiogenesis-driven inflammatory response in
vulnerable plaques, offers new opportunities for functional
imaging of biological activities in atherosclerosis. Since
specific molecular mechanisms (matrix synthesis and
proteolysis) are also implicated in the development of
aneurysmal and occlusive disease, other modalities ford by Elsevier Ltd. All rights reserved.
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possible.
Better understanding of the pathogenesis and natural
history of these processes, with the goal of improving the
treatment of atherothrombosis and aortic aneurysm, should
be an important goal for physicians. Therefore, the goal is
to identify functional imaging methods to inform about
both biological mechanisms and disease prognosis, partic-
ularly with respect to the prediction of impending rupture
of aneurysms and vulnerable plaques.Haemorrhage and Thrombosis: a Common
Pathway in Vulnerable Plaques and AAA
Compared to the role of lipids and immuno-inflammation1
in the initiation and progression of atheromatous diseases,
the biological determinants of plaque or wall rupture are
less well documented in humans. The involvement of
repeated intra-plaque haemorrhages in the evolution of
atherothrombotic lesions was proposed as early as 1938.2
This important topic has been recently revisited by
Kolodgie et al.3 They found an association between unes-
terified cholesterol accumulation and specific red blood
cell (RBC)-antigen expression. Platelet membranes also
participate in cholesterol accumulation.4 The intra-plaque
haemorrhage, leading to the formation of a necrotic core,
includes all blood components: RBCs, leukocytes (70%
neutrophils), platelets5 and plasma proteins, all of which
are retained by encapsulation of the core between the cap
and the media.
AAA is another frequent form of atherothrombosis.6 AAA
is the archetypal human model of proteolytic injury of the
arterial wall leading to rupture.7 Intra-luminal thrombus
(ILT) activities are polarised: initiated at the luminal
interface by circulating blood, these activities are
progressively conveyed towards the aneurysm wall. Luminal
platelet activation and fibrin formation bring zymogens
from the blood towards the aneurysm wall, thus partici-
pating in the extracellular matrix degradation.8 On the
abluminal pole, ILT is completely degraded and resembles
the necrotic core of vulnerable plaque. Therefore, AAAs
represent an accessible spatio-temporal pathophysiological
model of human atherothrombosis, allowing a study of the
associations between biological activities and clinical
expression.Inflammation and Angiogenesis: a Common
Response to Vulnerable Plaque and AAA
As early as 1938, in parallel with the observations of intra-
plaque haemorrhage in vulnerable plaques, Paterson9
reported the development of neo-capillaries in complicated
plaques and their involvement in sub-intimal haemorrhage.
Such observations led Barger et al.10 to propose that neo-
angiogenesis influences the progression of atherosclerosis.
In their remarkable study, using post-mortem micro-
angiography and corresponding histological examination of
coronary arteries, Kumamoto et al.11 demonstrated that
neo-vascularisation of the atherosclerotic plaque origi-
nated mainly from the adventitia and rarely from thelumen. In humans, these neo-capillaries develop mainly in
the shoulder of the complicated plaque, at the interface
between the core, the cap and the media. These neo-
capillaries would allow diffusion of plasma-borne molecules
and leukocyte diapedesis. Indeed, the density of intimal
neo-capillaries correlated with the extent of core forma-
tion, haemosiderin deposits, haemorrhage and inflamma-
tory infiltrates, suggesting that centripetal angiogenesis is
linked to the evolution of atherothrombosis. Similar data on
neo-vascularisation have been reported in human carotid
plaques12e14 and the aorta,15 correlating in all cases with
plaque evolution.
Although monocytic cell migration from blood to the
intima is thought to be mainly aimed at phagocytosis and
initiation of the early atheromatous process, inflammatory
infiltrates are present in the shoulder region of the lesion
core and in the adventitia adjacent to complicated
plaques. A mononuclear cell infiltration associated with
atheromatous plaques was reported by Gerlis, in 1956, in
coronary arteries16 and by Schwartz and Mitchell, in
1962.17
In AAA, proteolytic injury results in initiation of inflam-
mation, oedema and lymphoid neo-genesis in the adven-
titia. Inflammatory cell retention and lymphoid neo-genesis
are linked to capillary development in the adventitia in
AAA.18 Neo-angiogenesis in the outer part of the AAA was
described more than 10 years ago.19 The authors showed
strong spatial correlations between neo-capillaries, degra-
dation of elastin and the extent of the inflammatory infil-
trate in the outer aortic wall.19 However, in contrast to
vulnerable plaques or occlusive thrombus,20 neo-vessels do
not colonise the media and the luminal thrombus in AAA,
probably because of a local excess of proteolytic activities.
Therefore, imaging techniques enabling visualisation of
both biological processes involved in the processes of
haemorrhage and thrombus formation and angiogenetic
inflammation would be highly desirable.X-Ray and CT Scan
Calcification is a common feature in all forms of athero-
sclerosis and is easily identifiable by X-ray. Calcium phos-
phate precipitation and retention in soft tissue are linked
to cell death and membrane-particle formation and to
trans-differentiation of smooth muscle cells. In AAA,
calcifications are usually localised in the medial layer,
defining not only the external side of the aneurysmal dila-
tation, but also occasionally within the ILT. These medial
calcifications potentially are linked to smooth muscle
death. In addition, interfaces between calcified and normal
tissue create areas of high stress and strain, which could
increase extracellular matrix sensitivity to breakdown.
Calcifications are frequently present in plaques, creating
‘artefacts’ for ultrasound and MRI. They could be an
important determinant of plaque evolution by proliferating
within the lumen and creating stenosis and ‘hot spots’ for
thrombosis. Calcifications are particularly frequent in the
iliac and femoral arteries. Automatic quantification of
calcified areas has long been suggested as a useful prog-
nostic tool in coronary artery disease,21 but has not been
used widely in peripheral arterial disease.
730 N. Sakalihasan, J.B. MichelCrescent sign in AAA. The crescent sign, caused by
contrast entering the intra-luminal thrombus and high
attenuation within ILT detected by CT scan, was reported
some time ago.22 The crescent sign corresponds to ‘lique-
faction’ or bleeding into the intra-luminal thrombus.23
Since the bleeding comes directly from the lumen, this sign
is best appreciated in the arterial phase of the scan.
Subsequently, this morphological sign has been correlated
with an impending risk of aneurysmal rupture.24e26 This
imaging of bleeding into the ILT has been recently reviewed
and showed a high association between AAA rupture and
the presence of a crescent sign.27 The crescent sign can
also be demonstrated and analysed with MRI.
Magnetic Resonance Imaging (MRI)
In both, haemorrhagic areas and thrombus, the erythrocytic
component releases paramagnetic iron from haem, which
can be identified based on the T1-weighted shortening
effect, and by the signal loss associated with iron deposi-
tion when T2-weighted (T2W) gradient-echo or T2W spin-
echo sequences are used.28 The presence of the T2W
negative signal is associated with the presence of cells
capable of phagocytosing haemosiderin and storing it as
intracellular ironeferritin complexes. These are primarily
macrophages and polynuclear neutrophils. Other accessory
phagocytic cells, such as smooth muscle cells,29 and other
biological processes associated with binding and concen-
trating iron cannot be excluded. Nevertheless, signal loss
and negative contrast obtained using conventional T2/T2W
may lack sensitivity and specificity, because of the low
relaxivity of iron (sensitivity), and can be confused (speci-
ficity) with the signal loss caused by other sources, such as
partial-volume artefact.
Therefore, imaging of iron phagocytic activity could be
enhanced by iron-particle contrast agents, such small
paramagnetic iron oxide (SPIO) or other formulations of iron
particles. These exogenously injected iron particles should
be phagocytosed, thereby enhancing the T2W sequences.
30
Recently, more specific and sensitive sequence analyses,
such as gradient-echo acquisition for superparamagnetic
particles/susceptibility (GRASP), have been proposed for
positive imaging of tissue iron retention.31
Histological observations of intra-plaque haemorrhages
compared with MRI of human carotid atheroma allowed
identification of intra-plaque haemorrhage32,33 as the main
determinant of plaque evolution.34
Scintigraphy
Single photon emission computed tomography (SPECT) is
a tomographic imaging technique using gamma rays. It is
very similar to conventional planar nuclear medicine
imaging using a gamma camera. However, it is able to
provide true three-dimensional information. This informa-
tion is typically presented as cross-sectional slices through
the patient, but can be freely reformatted ormanipulated as
required. Imaging of atheromatous plaques has traditionally
centred on assessing the degree of luminal narrowing;
indeed,myocardial perfusion imaging is a routinely used tool
for exploring such functional haemodynamic consequences.More recently, it has become clear that it is of utmost
importance to identify vulnerable atherosclerotic plaques
responsible for the majority of life-threatening syndromes.
Molecular imaging using nuclear medicine techniques has
the potential to characterise the activity of atheromas.
Annexin V specifically binds, with nanomolar affinity, to
phosphatidyl serine (PS), which is exposed on the surface of
activated platelets35 and apoptotic cells.36 Therefore,
radiolabelled 99mTc-annexin-V has been used for in vivo
scintigraphic imaging of both apoptotic cells in animals and
humans37 and acute or chronic platelet-rich thrombi in
animals.38,39 In a recent study, we have shown the ability of
99mTc-annexin-V to assess the renewal activity of chronic
aseptic intra-luminal thrombi, at the interface between
circulating blood and thrombus, in an in vivo experimental
model of AAA, and ex vivo in human ILT.37 In another study,
we extended this result to experimental endocarditis and
demonstrated that 99mTc-Annexin-V can be used for visu-
alising thrombotic vegetations e an observation that was
confirmed in a case report of endocarditis in a human
patient.40 Moreover, 99mTc-Annexin-V scintigraphy also
could help to localise peripheral emboli, and thus could
probably be used to evaluate therapeutic efficacy.
Since exposure of PS is one of the mediators of platelet-
activation-induced fibrin formation, 99mTc-Annexin-V
imaging could provide noninvasive functional information
on the renewal rate of haemo-thrombus, which is
constantly in contact with flowing blood. Unfortunately,
despite the tremendous potential of 99mTc-Annexin-V
imaging in cardiovascular diseases, this radiotracer is not
yet commercially available for clinical use.
In addition to annexin V, lactadherin is capable of
binding to PS of any origin, whether from platelets and/or
cell apoptosis.41,42 Lactadherin can also bind PS as well as
a(v) b(5) and (3) integrin.43 The potential of this ligand for
molecular imaging has not yet been explored.
Another peptidic (13 amino acids, cyclo-(D-Tyr-Apc-Gly-
Asp-Cys)-Gly-Gly-Cys(Acm)-Gly-Cys(Acm)-Gly-Gly-Cys-NH2)
ligand of GPIIb/IIIa has been developed, 99mTc-Apcitide44
(Acutect, Diatide, USA) for visualising biological activity
associated with thrombi.45,46 This radiotracer is mainly
proposed for exploring deep venous thrombosis and
pulmonary embolism.47
Since proteolytic activity plays a major role in the
rupture of the arterial wall associated with plaque and/or
AAA, imaging this multifactorial biological process, possibly
including the fibrinolytic pathway, could be an interesting
challenge. Aprotinin is a purified bovine lung protein with
powerful affinity for plasmin. It is used as a therapeutic
agent in human disseminated intravascular coagulation
(Trasylol). Aprotinin radionuclide (99mTc-aprotinin) already
has been used in humans for imaging amyloid deposits48 to
which plasmin binds.49 This provides the future possibility
of imaging plasmin activity in vivo.Positron Emission Tomography (PET)
PET imaging was developed in the mid-1970s; like any
nuclear medicine imaging technique, it is based on the
detection of photons emitted by the patient after admin-
istration of a radio-labelled tracer. Several physical
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monophotonic scintigraphy. Most importantly, the tracers
are labelled with positron-emitting radionuclides. The two
photons resulting from the disintegration of the positron
are emitted in opposite directions (i.e., at 180 from each
other) and recorded in coincidence by the detectors
surrounding the subject. A detailed description of the
specific technical and methodological features of PET
imaging is obviously beyond the scope of this article and
may be found in Phelps.50 In short, PET imaging increases
the count rate (i.e., the number of photons that are
detected) and improves the spatial resolution, that is,
lesion detectability. In addition, the images can be fully
corrected, in particular for attenuation, which allows for an
accurate and reproducible quantitation of tracer
distribution.
Depending on the radiotracer, a wide variety of physio-
logical and pathological processes can be studied at the
molecular level using this technique. However, in routine
clinical practice, vast majority of PET studies are per-
formed using 18-F-fluorodeoxyglucose (FDG), which reflects
glucose uptake and metabolism resulting from cellular
activity.
FDG is a glucose analogue, transported into cells using
glucose transporters. Once inside the cells, FDG is phos-
phorylated to FDG-6-phosphate, which is not a substrate for
the enzymes of the glycolytic chain, and hence FDG-6-
phosphate accumulates within the cell. FDG-PET recognises
increased metabolic activity and is mainly used for cancer
imaging. Indeed, cell glucose metabolism is significantly
increased in most types of cancer51 due to increased
expression of membrane transporters, increased hexokinase
activity or both. Nevertheless, FDG uptake is not specific for
tumours. Increased uptake is observed in many non-
neoplastic physiological and pathological conditions.52
Usually, the level of FDG uptake by inflammatory cells in the
resting state is low in comparison with tumour cells.
However, when activated, these cells may show significant
increases in glucose uptake and metabolism. This has been
evaluated in various experimental settings, including skin
transplantation, turpentine-induced inflammation, con-
cavalin-A activation of T lymphocytes in bacterial abscesses
or in B lymphocytes after viral infection. The lack of speci-
ficity for tumours provides a powerful tool for using PET to
evaluate inflammatory and infectious diseases as well as
during the monitoring of vascular graft infection.53e55 It
should be noted, however, that FDG uptake is often seen in
the arterial wall, in the absence of any known inflammatory
vascular disease. Yun et al. evaluated two series of patients
who underwent PET imaging for oncological or other indi-
cations. They found that the rate of positive vessel uptake
approached 50% and increased with age.56 They also showed
that hypercholesterolaemia and age were the only param-
eters correlatedwith the presence of such uptake, among all
major risk factors for atherosclerosis.57
With the advent of modern PET/CT, the procedure has
been considerably shortened and simplified. Usually,
patients are asked to fast for 6 h prior to injecting FDG,
which is of particular importance when investigating
inflammatory processes, as glucose loading significantly
decreases glucose transporter expression (and FDG uptake)
in inflammatory lesions.58 Modern hybrid scanners arecoupled with CT for attenuation correction and anatomical
mapping. Attenuation correction is usually performed using
data from continuous, enhanced, low-dose body CT from
the skull base to the thighs. Intravenous contrast enhance-
ment can be used with limited effects on attenuation
correction and uptake quantification in order to provide
additional information on the thrombus, surrounding tissues
and vessels.
Wu et al.59 demonstrated the uptake of 18F-FDG in the
unstable atherosclerotic carotid plaque and correlated this
with levels of circulating matrix metalloproteinase 1 (MMP-
1). Other workers have shown the high uptake of FDG into
vulnerable atherosclerotic plaque60 and the reduction of
carotid FDG uptake after statin therapy. This suggests that
PET imaging might have clinical utility in monitoring
atherosclerotic arterial disease.61
Using autoradiographic techniques, Rudd et al. showed
increased tracer accumulation in the regions of the plaque
with the highest density of macrophages.62 Indeed,
enhanced uptake has been reported in various inflamma-
tory diseases involving the large vessels. Giant cell arteritis
and Takayasu arteritis both show significantly increased
glucose metabolism in the wall of the affected arteries
(i.e., aorta, subclavian arteries or carotid arteries).54
Furthermore, FDG uptake has been found in large arteries
in the presence of active atheromatous plaques.56,57
In a pilot study, Sakalihasan et al. observed an associa-
tion between 18-FDG uptake by the aneurysm wall and
rapid expansion of the aneurysm in some cases.63 Indeed,
five of the nine operations on patients with positive PET
imaging were performed on an urgent basis. In the 16 PET-
negative patients, aneurysmal repair was delayed for the
convenience of the patient from one to several months.
None of these patients developed aneurysm-related symp-
toms in the interval.
FDG uptake in the aneurysm wall reflects the presence of
increasedmetabolic activity, probably associatedwith ahigh
density of inflammatory cells (macrophages, lymphocytes,
etc.) in the adventitia, as previously described.64 These
preliminary observations have been confirmed recently in
a study by Reeps et al.,65 where they observed a correlation
between increased FDG uptake and patients with a very high
macrophage activity and symptomatic AAA. However, in
agreement with earlier reports,63 Reeps et al. failed to find
a correlation between the maximum standard uptake value
(SUV) and maximum cross-sectional infra-renal AAA diam-
eter.65 These studies could suggest a possible correlation
between increased FDG uptake by the aneurysm wall and
inflammatory cell biology leading to rupture.
Therefore, PET scanning with FDG uptake offers a new
tool for exploring adventitial immuno-inflammatory
responses in atherosclerosis and AAA.New Ligands and Contrast Ultrasonography
The biology of human atherothrombotic processes is
complex, and the possible molecular and cellular targets are
numerous. Several biological processes could be targeted by
molecular imaging including: lipid retention, platelet acti-
vation and aggregation, coagulation and fibrin formation,
proteolysis (including MMP activities66), serine proteases
Table 1 Functional imaging of pathobiological processes
in the vasculature




macrophages in the arterial wall
MRI Haemosiderin deposits
in the arterial wall
SPECT Apoptosis, activated platelets
Contrast
ultrasonography
Neo-vascularisation and cell receptors
732 N. Sakalihasan, J.B. Michel(plasmin, elastase, etc.), free extracellular haemoglobin,
etc. Here there are opportunities for contrast-enhanced
ultrasonography.67 Protein or peptide ligands (including
antibodies) can be attached to the micro-bubbles used for
contrast to target endothelial epitopes, leukocyte adhesion
molecules and angiogenesis receptors.67
Conclusion
Multimodal imaging, associated with different comple-
mentary methods such as CT scan and PET, MRI and scin-
tigraphy and contrast ultrasonography, will improve the
definition of the atherothrombotic lesion and its pathobi-
ology. The biological process imaged by these different
imaging techniques are summarised in Table 1. The use of
several complementary methods associated with morpho-
logical, functional and molecular analysis could allow
a better definition of the prognosis of the lesion.
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